TRBV7-2: A Potential Drug Target and Biomarker for T Cell Receptor Beta Variant 7-2

Target Name: TRBV7-2

NCBI ID: G28596

TRBV7-2

Other Name(s): T cell receptor beta variable 7-2 | TCRBV7S2 | TCRBV6S5A1N1 | TCRBV6S5A2 | TRBV72

TRBV7-2: A Potential Drug Target and Biomarker for T Cell Receptor Beta Variant 7-2

T cells are a crucial part of the immune system, and their activity is regulated by various proteins, including T cell receptor (TCR) beta molecules. TRBV7-2 is a well-known T cell receptor beta variant that has been identified as a potential drug target and biomarker.

TRBV7-2 is a 21-kDa protein that is expressed in a variety of tissues, including spleen, lung, brain, and heart. It is a single-pass T cell receptor alpha chain and consists of a variable region and a constant region. The variable region contains the majority of the T cell receptor alpha chain diversity, including the 伪1, 伪2, and 伪3 subunits.

TRBV7-2 has been shown to play a critical role in T cell development and activation. It is expressed in the T cell receptor alpha chain and is involved in the formation of the T cell receptor alpha chain complex. This complex is composed of the TRBV7 -2 protein, as well as the alpha chain subunits.

Research has also shown that TRBV7-2 is involved in the regulation of T cell responses to antigens. When T cells recognize an antigen, TRBV7-2 is activated and regulates the activation and proliferation of the T cells. This suggests that TRBV7-2 may be a useful drug target for T cell-related diseases.

TRBV7-2 has also been shown to be involved in the regulation of inflammation. When T cells are activated by an antigen, TRBV7-2 is activated and regulates the production of cytokines, such as interleukin-2 (IL-2). This suggests that TRBV7-2 may be a useful biomarker for evaluating the activity of anti-inflammatory drugs.

In addition to its potential drug-related applications, TRBV7-2 is also a potential biomarker for certain diseases. For example, TRBV7-2 has been shown to be expressed in a variety of cancer types, including lung, breast, and ovarian cancer. This suggests that TRBV7-2 may be a useful biomarker for cancer diagnosis and treatment.

TRBV7-2 has also been shown to be involved in the regulation of immune cell function. When immune cells are activated, TRBV7-2 is activated and regulates the production of antibodies, as well as the activation and proliferation of the immune cells. This suggests that TRBV7-2 may be a useful target for immune-related diseases.

In conclusion, TRBV7-2 is a well-known T cell receptor beta variant that has been shown to play a critical role in T cell development, regulation, and inflammation. Its potential drug target and biomarker status make it an attractive target for further research and development. Further studies are needed to fully understand the role of TRBV7-2 in T cell biology and its potential as a drug and biomarker.

Protein Name: T Cell Receptor Beta Variable 7-2

Functions: V region of the variable domain of T cell receptor (TR) beta chain that participates in the antigen recognition (PubMed:24600447). Alpha-beta T cell receptors are antigen specific receptors which are essential to the immune response and are present on the cell surface of T lymphocytes. Recognize peptide-major histocompatibility (MH) (pMH) complexes that are displayed by antigen presenting cells (APC), a prerequisite for efficient T cell adaptive immunity against pathogens (PubMed:25493333). Binding of alpha-beta TR to pMH complex initiates TR-CD3 clustering on the cell surface and intracellular activation of LCK that phosphorylates the ITAM motifs of CD3G, CD3D, CD3E and CD247 enabling the recruitment of ZAP70. In turn ZAP70 phosphorylates LAT, which recruits numerous signaling molecules to form the LAT signalosome. The LAT signalosome propagates signal branching to three major signaling pathways, the calcium, the mitogen-activated protein kinase (MAPK) kinase and the nuclear factor NF-kappa-B (NF-kB) pathways, leading to the mobilization of transcription factors that are critical for gene expression and essential for T cell growth and differentiation (PubMed:23524462). The T cell repertoire is generated in the thymus, by V-(D)-J rearrangement. This repertoire is then shaped by intrathymic selection events to generate a peripheral T cell pool of self-MH restricted, non-autoaggressive T cells. Post-thymic interaction of alpha-beta TR with the pMH complexes shapes TR structural and functional avidity (PubMed:15040585)

The "TRBV7-2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRBV7-2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets